{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Merus N.V."},"Symbol":{"label":"Symbol","value":"MRUS"},"Address":{"label":"Address","value":"YALELAAN 62, UTRECHT, 3584 CM, Netherlands"},"Phone":{"label":"Phone","value":"+31 302538800"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.merus.nl"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Cecilia Anna Wilhelmina Geuijen","title":"Chief Scientific Officer & Senior Vice President"},{"name":"Ernesto Wasserman","title":"Senior Vice President-Clinical Development"},{"name":"Fabian Zohren","title":"Chief Medical Officer"},{"name":"John de Kruif","title":"Chief Technology Officer & Senior Vice President"},{"name":"Peter B. Silverman","title":"Chief Operating Officer, EVP & General Counsel"},{"name":"Sven Ante Lundberg","title":"President, CEO & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}